新型疗法 MAR001 在二期临床试验中显著降低甘油三酯水平
In phase 2 trial, novel therapy significantly reduced triglyceride levels
一项由马萨诸塞州总医院心血管研究所领导的二期临床试验显示,新型抗体疗法 MAR001 能显著降低高甘油三酯患者的水平。试验结果显示,MAR001 在 12 周内将甘油三酯水平降低了 39.1% 至 45.5%,且未增加不良反应。
报道了新型疗法 MAR001 在降低高甘油三酯水平方面的有效性和安全性。
A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. Their results are published in the New England Journal of Medicine and were presented simultaneously at the American Heart Association's annual meeting.
"Despite advances in lipid-lowering therapy, many patients continue to have elevated triglyceride levels and cardiovascular risk," says lead author Michelle O'Donoghue, a cardiologist with the Mass General Brigham Heart and Vascular Institute and senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group. "Our findings suggest that MAR001 may be able to safely and effectively lower triglycerides."
Several classes of drugs have been previously shown to lower triglycerides, but MAR001 is novel because it targets ANGPTL4, a protein that naturally inhibits lipoprotein lipase, an enzyme that breaks down triglycerides.
The researchers tested the effectiveness of three different doses of MAR001 in 235 participants with elevated triglyceride levels. Participants were randomly assigned to receive either a placebo or 300, 450 or 900 mg of MAR001 subcutaneously every four weeks for 24 weeks. The trial was designed by the Mass General Brigham Thrombolysis in Myocardial Infarction (TIMI) Study Group with the sponsor Marea Therapeutics, and participants received treatment at 48 centers across the United States, Canada, Australia and New Zealand.
MAR001 was effective at lowering fasting triglyceride levels and demonstrated a statistically significant, placebo-adjusted reduction in fasting triglyceride levels of 39.1% to 45.5% across three MAR001 dose levels at week 12. MAR001 treatment was not associated with more frequent adverse effects compared to the placebo.
More research is needed to understand the long-term effects and to assess whether these reductions in triglycerides reduce the risk of pancreatitis and other complications of high triglycerides. In the next phase of the study, the researchers will test MAR001 in participants with severely elevated levels of triglycerides.
"We observed greater reductions in triglycerides in participants with higher baseline triglyceride levels," says O'Donoghue. "We're now evaluating this in a dedicated follow-up study."
Publication details
ANGPTL4 Inhibition in Adults with Elevated Triglycerides, New England Journal of Medicine (2026). DOI: 10.1056/NEJMoa2612463
Journal information: New England Journal of Medicine
Key medical concepts
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: In phase 2 trial, novel therapy significantly reduced triglyceride levels (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-phase-trial-therapy-significantly-triglyceride.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com